Clinical Trials
6 trialsNCT03789240 2026-03-03
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT02367040 2025-10-14
CHRONOS-3
Bayer
Phase 3 Completed
NCT02626455 2024-12-11
CHRONOS-4
Bayer
Phase 3 Terminated
NCT01660451 2024-07-17
Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Bayer
Phase 2 Completed
NCT02369016 2023-11-18
CHRONOS-2
Bayer
Phase 3 Completed
NCT04155840 2022-04-11
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
University of Washington
Phase 2 Terminated